Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Reexamination Certificate
2005-08-23
2005-08-23
Canella, Karen A. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
C530S387200
Reexamination Certificate
active
06932968
ABSTRACT:
Erythropoietin (EPO) peptides and the use thereof for preparing epitope-specific anti-EPO antibodies are described. Also described are corresponding anti-EPO antibodies which take the form of polyclonal antibodies (antisera) or of monoclonal antibodies. These antibodies are suitable for purifying EPO, EPO derivatives or EPO peptides. The epitope-specific anti-EPO antibodies according to the invention can also be used for the detection of EPO and, in particular, for the epitope-specific detection of EPO. Additionally described are anti-idiotype antibodies which imitate a receptor region of EPO. Finally, pharmaceuticals which contain the EPO peptides, anti-EPO antibodies or anti-idiotype antibodies, and diagnostic aids for the detection of EPO or of anti-EPO antibodies, are described.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4558005 (1985-12-01), Goldwasser et al.
patent: 4558006 (1985-12-01), Egrie
patent: 4590168 (1986-05-01), Sytkowski et al.
patent: 4703008 (1987-10-01), Lin
patent: 4722899 (1988-02-01), Hamaoka et al.
patent: 4748018 (1988-05-01), Stolle et al.
patent: 5712370 (1998-01-01), Fibi et al.
patent: A 116446 (1984-08-01), None
patent: WO85/02610 (1985-06-01), None
patent: 86/04068 (1986-07-01), None
Accession No. NP 058698, Nov. 2000.
Accession No. NP 000790, Oct. 2000.
Philo et al, Biochemistry, 1996, vol. 35, pp. 1681-1691. (abstract).
Narhi et al, Journal of Protein Chemistry, 1997, vol. 16, pp. 213-225. (abstract).
Wojchowski et al, Biochimica et Biophysica Acta, 1987, vol. 913, pp. 170-178.
Kaplan et al, In:Monoclonal Antibodies in Clinical Medicine, 1982, pp. 1-2, A. J. McMichael and J. W. Fabre, Ed.s.
Miyazaki et al, Journal of immunological Methods, 1988, vol. 113, pp. 261-267.
Seaver, Genetic Engineering News, pp. 10 and 21 (1994).
Borrebaeck, Journal of Immunological Methods, vol. 123, pp. 157-165 (1989).
Lee-Huang, Fed. Proc., vol. 41, Abstract No. 1463, p. 520 (1982).
Goto et al., Blood, vol. 74, No. 4, pp. 1415-1423 (Sep. 1989).
Graber et al., Ann Rev. Med. 29:51-66 (1978).
Miyake et al., J. Biol. Chem., 252:5558-5564 (1977).
“Erythropoietin,” The Lancet, pp. 781-782 (1987).
Eschbach et al., The New England Journal of Medicine, vol. 316, No. 2, pp. 73-78 (1987).
Sytkowski et al., J. Biol. Chem., 262:1161-1165 (1987).
Axen et al., Nature, 214:1302-1304 (1967).
Lai et al., Journal Biol. Chem., vol. 261, No. 7, pp. 3116-3121 (1986).
Fibi Mathias
Stüber Werner
Canella Karen A.
Dade Behring Marburg GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
LandOfFree
Erythropoietin (EPO) peptides and antibodies directed... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Erythropoietin (EPO) peptides and antibodies directed..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietin (EPO) peptides and antibodies directed... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487510